OxySure Systems, a medical technology company that has pioneered an FDA-approved solution to produce medically pure oxygen from dry, inert powders for emergency/short duration use, was reiterated with a Speculative Buy rating from analysts at Taglich Brothers. Taglich Brothers set a 12-month price target of $2.10 on the stock.
In the research update, Taglich Brothers also raised its revenue estimates for OXYS in anticipation of higher sales partially attributable to the company's military business. The research firm expects sales to rise from $2 million in 2013 to $4.9 million in 2015. By 2017, revenues are projected to increase to $18 million.
To see the 15-page report in its entirety, follow the link posted under additional resources at dtg.fm/oxys.
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net